Is Gilead Sciences Stock a Buy Now?

With the market shifting away from richly valued speculative growth stocks lately, it might be worth it for investors to consider investing in companies that are established leaders within their fields, particularly those that have lagged the market recently and have become cheap as a result.

At first glance, this description fits Gilead Sciences (NASDAQ: GILD), one of the largest biotechs in the world with a forward price-to-earnings (P/E) ratio of 10, compared to the industry's average of 11.

Of course, before making a final decision to invest in this drugmaker, it's essential to look a bit closer at its business. Let's dig in and decide whether Gilead Sciences is as attractive an investment as it seems. 

Continue reading

Source Fool.com